Management tracks

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) hired David Berman as SVP and head of its oncology innovative medicines unit. He will succeed Edward Bradley, who will serve in an advisory role until he retires at YE16. Berman was VP and head of the immuno-oncology exploratory development team at Bristol-Myers Squibb Co. (NYSE:BMY).

Ophthalmology company Ophthotech Corp. (NASDAQ:OPHT) hired David Shima as CSO, Henric Bjarke as SVP and chief commercial officer, and Satish Tripathi as SVP of global regulatory affairs. Shima was global head and VP of ophthalmology discovery and biomarkers at Roche (SIX:ROG; OTCQX:RHHBY). Bjarke was VP of the global metabolic disorders franchise at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN); he replaces Todd Smith, who is departing. Tripathi was VP of global regulatory affairs and clinical quality assurance at InterMune Inc., which Roche acquired. ...